RNASEL associated cancer
Reading File
Searching PubMed
RNASEL cancer hereditary prostate
Finding Sources
Searching the Web
RNASEL gene cancer mechanism RNase L tumor suppressor 2024
Searching PubMed
RNASEL tumor suppressor innate immunity cancer
Reading File
Reading File
Reading Article
PMID: 20576793
Finding Sources
Reading Web Page
https://pmc.ncbi.nlm.nih.gov/articles/PMC3468953
I now have enough information for a comprehensive answer.
RNASEL and Associated Cancers
Gene Overview
RNASEL (also called RNS4 or PRCA1) encodes Ribonuclease L (RNase L), a latent, ubiquitously expressed endoribonuclease located at chromosome 1q25.3. It is the terminal effector of the 2-5A pathway - a key arm of the type I interferon (IFN) antiviral response. RNase L is activated when 2',5'-linked oligoadenylate (2-5A) molecules bind its ankyrin-repeat domain, causing it to dimerize and cleave both viral and cellular single-stranded RNA.
The 2-5A/RNase L Pathway
The activation cascade is:
- Interferons (IFN-α/β) are secreted in response to viral infection or innate immune sensing.
- IFNs induce oligoadenylate synthetases (OAS), which synthesize 2-5A from ATP when activated by double-stranded RNA (dsRNA).
- 2-5A binds and activates RNase L, which cleaves viral/cellular ssRNA.
- Cleavage products activate RIG-I/MDA5 (pattern recognition receptors), amplifying the IFN response.
- RNase L also triggers apoptosis in virus-infected cells, limiting viral spread.
RNASEL as a Tumor Suppressor
RNase L functions as a tumor suppressor through multiple mechanisms:
| Mechanism | Detail |
|---|---|
| Antiviral defense | Eliminates oncogenic viruses (e.g., retroviruses, HPV, XMRV) before transformation |
| Apoptosis induction | Activates intrinsic and extrinsic apoptotic pathways in damaged/transformed cells |
| HuR downregulation | RNase L suppresses the RNA-binding protein HuR, which normally stabilizes growth-promoting mRNAs including cyclin D1, c-myc, uPA, and COX-2 |
| MMP suppression | Reduces matrix metalloproteinase activity, limiting invasion and metastasis |
| Replicative senescence | Promotes cellular senescence; RNASEL-knockout mice show extended lifespan with increased tumorigenesis risk |
| ABCE1 inhibition | ABCE1 (also called OABP) is an inhibitor of RNase L; overexpression of ABCE1 can abrogate RNase L function |
Key Germline Variants
| Variant | Type | Effect | Significance |
|---|---|---|---|
| R462Q (rs486907) | Missense (Arg→Gln) | 3-fold reduction in RNase L activity; ~2x increased prostate cancer risk in homozygotes | Implicated in up to 13% of prostate cancer cases (Casey et al., Nature Genetics, 2002) |
| E265X | Nonsense | Truncated, non-functional protein | Found in HPC families |
| D541E | Missense | Reduced activity; associated with advanced-stage disease | Population-dependent effect |
| rs12757998 (AA homozygotes) | SNP | OR 1.63 for prostate cancer; OR 1.90 for high-grade (Gleason ≥7) tumors; elevated CRP and IL-6 | Supports inflammation-mediated oncogenesis (Meyer et al., Carcinogenesis, 2010, PMID 20576793) |
Cancer Associations
1. Hereditary Prostate Cancer (HPC) - Primary Association
RNASEL sits at the HPC1 locus (1q24-25), the first hereditary prostate cancer locus identified by genome-wide linkage analysis. Key points:
- Linkage to HPC1 was identified in the 1990s; RNASEL was confirmed as the candidate gene in 2002 (Carpenten et al., Rokman et al.).
- Family history is a major prostate cancer risk factor, with a heritable component of ~50% estimated from twin studies.
- RNASEL variants account for familial clustering in a subset of HPC families - but linkage replication has been inconsistent, reflecting the polygenic nature of the disease.
- RNASEL is listed alongside MSR1 (macrophage scavenger receptor-1) and ELAC2 (HPC2 locus) as the main HPC candidate genes in genitourinary oncology references, as cited in Campbell-Walsh-Wein Urology (p. 62.12).
- Early-onset prostate cancer (<55 years) has a stronger heritable component, and RNASEL variants disproportionately affect younger-onset families.
According to Emery's Elements of Medical Genetics and Genomics: "Variants in the gene encoding ribonuclease L (RNASEL) were identified in two families showing linkage to the HPC1 locus at 1q25." The same textbook notes that RNASEL accounts for only a fraction of HPC cases - the majority remains genetically unexplained.
2. Other Cancers
Beyond prostate cancer, RNASEL has been investigated in:
| Cancer Type | Evidence |
|---|---|
| Colorectal cancer | RNASEL variants found in HNPCC/familial colorectal cancer families; listed as a candidate gene at the same HPC1 locus region |
| Uterine/endometrial cancer | Reported in HPC families with multi-site cancer phenotypes |
| Head and neck cancer | Reduced RNase L activity observed |
| Cervical cancer | TTP (tristetraprolin, an RNase L-regulated ARE-mRNA regulator) expression linked to proliferation and chemosensitivity |
| Breast cancer | Some families with both breast and prostate cancer carry RNASEL variants; BRCA1/2-negative families sometimes harbor RNASEL mutations |
The association is strongest and best-replicated for prostate cancer. For other cancers, the evidence is more limited and inconsistent.
Viral Oncogenesis Link
A compelling but contested dimension is RNase L's role in defending against oncogenic viruses:
- XMRV (xenotropic murine leukemia virus-related virus): Initially detected in prostate tumors of patients with the R462Q variant; the hypothesis was that impaired RNase L allowed XMRV persistence. However, XMRV was later determined to be a lab contaminant, tempering this line of research.
- Impaired RNase L activity may generally allow persistent infection by oncogenic RNA viruses, creating a permissive environment for transformation.
Clinical & Genetic Counseling Implications
- RNASEL testing is not standard clinical practice in most guidelines (unlike BRCA1/2 for prostate cancer).
- Men with a strong family history of early-onset prostate cancer, particularly those with HNPCC-associated mutations (MSH6, PMS1/2, MLH3), should be aware that RNASEL/MSR1/ELAC2 overlap in familial risk.
- PSA screening is offered to high-risk individuals; MRI +/- biopsy is emerging as a better screening modality.
- PARP inhibitor therapy is relevant for BRCA2-positive prostate cancer but not yet directly for RNASEL.
Summary
RNASEL is a tumor suppressor and innate immune effector. Its principal cancer association is hereditary prostate cancer (HPC1), where loss-of-function variants (especially R462Q) impair RNA degradation, antiviral defense, and apoptotic signaling - facilitating malignant transformation. The mechanism links chronic inflammation (elevated CRP, IL-6), viral permissiveness, and loss of HuR-regulated cell cycle control. While prostate cancer dominates the literature, emerging data implicate RNASEL dysfunction in colorectal, uterine, and possibly other cancers, though replication has been inconsistent.
Key references:
- Casey et al. Nature Genetics 2002, PMID 12415269 - R462Q in 13% of prostate cancers
- Meyer et al. Carcinogenesis 2010, PMID 20576793 - SNP rs12757998, inflammation, and cancer risk/progression
- Campbell-Walsh-Wein Urology, Chapter 62 (Hereditary Prostate Cancer)
- Emery's Elements of Medical Genetics and Genomics, Chapter 14 (Prostate Cancer genetics)
How many genes are directly involved in germline Cancer
Reading File
Searching PubMed
germline cancer predisposition genes number hereditary
Searching the Web
how many germline cancer predisposition genes known 2024 2025 complete list
Finding Sources
Reading Article
PMID: 24429628
Reading Article
PMID: 36150826
Finding Sources
Searching the Web
Rahman 2014 114 cancer predisposition genes TCGA 152 genes updated 2025
Finding Sources
Searching PubMed
cancer predisposition genes comprehensive catalog classification
Reading File
Reading File
Reading File
I now have comprehensive data to give a thorough, well-structured answer.
How Many Genes Are Directly Involved in Germline Cancer Predisposition?
The short answer is: the number depends on where you draw the line, and it has grown dramatically with genomic sequencing. Here is a breakdown by evidence tier:
The Key Numbers
| Source / Year | Gene Count | Basis |
|---|---|---|
| Rahman, Nature, 2014 (landmark catalog) | ~114 CPGs | 30 years of research; high-penetrance family study genes |
| TCGA germline analysis (Huang et al., 2018) | 152 CPGs | Extended from Rahman's 114; added pediatric CPGs from St. Jude PCGP; tested across 10,389 adult cancers in 33 cancer types |
| Illumina TruSight Hereditary Panel | 113 genes | Commercially curated clinical panel for germline risk |
| Harrison's (2025 edition) | "Roughly 100 familial cancer syndromes" | As stated in Chapter 76 |
| Expanding CPG studies (2020 onward) | >200 candidate genes | Ultra-rare cancer-exclusive variant studies; many still require validation |
| DNA damage repair gene studies (2025, JCO) | 180+ DDR genes analyzed | First comprehensive analysis of DDR genes for inherited cancer risk |
The most widely cited consensus figure is ~114-152 well-validated germline cancer predisposition genes (CPGs).
Why the Number Keeps Growing
- Next-generation sequencing (NGS) has replaced single-gene testing with multi-gene panel testing, uncovering lower-penetrance genes previously missed.
- Whole-exome and whole-genome sequencing in large cohorts (TCGA, UK Biobank, All of Us) continuously reveal new candidate genes.
- Pediatric cancer genomics has added genes specific to childhood cancers (e.g., DICER1, SMARCB1, PTCH1).
- Variants of uncertain significance (VUS) are being reclassified as pathogenic over time, expanding the actionable gene list.
Classification of Germline CPGs by Penetrance
| Category | Examples | Lifetime Cancer Risk |
|---|---|---|
| High-penetrance (>50% risk) | BRCA1, BRCA2, TP53, APC, RB1, VHL, RET, CDH1, STK11, SMAD4, NF1, NF2 | >50-90% |
| Moderate-penetrance (20-50%) | ATM, CHEK2, PALB2, BRIP1, RAD51C, RAD51D, NBN | 20-50% |
| Low-penetrance (<20%) | RNASEL, MSR1, various GWAS SNPs | Modestly elevated, often requires second hits |
Major Germline Cancer Syndromes and Their Key Genes
From Harrison's Principles of Internal Medicine (22nd ed., 2025, Table 76-3) and Sabiston Textbook of Surgery (Table 60.4):
| Syndrome | Gene(s) | Chromosome | Inheritance | Main Cancers |
|---|---|---|---|---|
| Hereditary breast/ovarian cancer | BRCA1, BRCA2 | 17q21, 13q12 | AD | Breast, ovarian, prostate |
| Lynch syndrome (HNPCC) | MSH2, MLH1, MSH6, PMS2 | 2p16, 3p21, 7p22 | AD | Colorectal, endometrial, ovarian, stomach |
| Familial adenomatous polyposis | APC, MUTYH | 5q21, 1p34 | AD/AR | Colorectal |
| Li-Fraumeni syndrome | TP53 | 17p13 | AD | Sarcoma, breast, brain, leukemia |
| Hereditary retinoblastoma | RB1 | 13q14 | AD | Retinoblastoma, osteosarcoma |
| Von Hippel-Lindau | VHL | 3p25 | AD | Renal cell, hemangioblastoma, pheochromocytoma |
| Multiple endocrine neoplasia (MEN1) | MEN1 | 11q13 | AD | Parathyroid, pituitary, pancreas |
| Multiple endocrine neoplasia (MEN2) | RET | 10q11 | AD | Medullary thyroid, pheochromocytoma |
| Neurofibromatosis type 1 | NF1 | 17q11 | AD | Neurofibromas, glioma, MPNST |
| Neurofibromatosis type 2 | NF2 | 22q12 | AD | Meningioma, acoustic neuroma |
| Cowden syndrome | PTEN | 10q23 | AD | Breast, thyroid, endometrial |
| Familial melanoma | CDKN2A | 9p21 | AD | Melanoma, pancreatic |
| Hereditary diffuse gastric cancer | CDH1 | 16q22 | AD | Stomach (diffuse type), lobular breast |
| Peutz-Jeghers syndrome | STK11/LKB1 | 19p13 | AD | GI, pancreatic, breast |
| Gorlin syndrome (basal cell nevus) | PTCH1 | 9q22 | AD | Basal cell carcinoma, medulloblastoma |
| Familial Wilms' tumor | WT1 | 11p13 | AD | Kidney (pediatric) |
| Hereditary renal papillary cancer | MET | 7q31 | AD | Papillary renal cell |
| Birt-Hogg-Dubé | FLCN | 17p11 | AD | Kidney, lung cysts |
| Ataxia telangiectasia | ATM | 11q22 | AR | Breast, lymphoma |
| Xeroderma pigmentosum | XPA-XPG, POLH | Multiple | AR | Skin cancers |
| Fanconi anemia | FANCA-FANCQ (>20 genes) | Multiple | AR | Leukemia, head and neck SCC |
| Bloom syndrome | BLM | 15q26 | AR | Various |
| Hereditary prostate cancer (HPC1) | RNASEL | 1q25 | AD | Prostate |
| Hereditary paraganglioma | SDHB, SDHC, SDHD, SDHA | Multiple | AD | Paraganglioma, pheochromocytoma |
| Tuberous sclerosis | TSC1, TSC2 | 9q34, 16p13 | AD | Renal angiomyolipoma, brain hamartoma |
Functional Pathways Enriched Among CPGs
Most of the ~152 validated CPGs cluster into a limited number of biological pathways:
- DNA damage repair (most common) - BRCA1/2, ATM, CHEK2, PALB2, RAD51C/D, MLH1, MSH2, MSH6, PMS2, BRIP1
- Cell cycle control / tumor suppression - TP53, RB1, CDKN2A, APC, PTEN, VHL
- RAS/MAPK / receptor tyrosine kinase signaling - RET, MET, NF1, HRAS
- PI3K/mTOR pathway - TSC1, TSC2, PTEN, FLCN, STK11, TMEM127
- SWI/SNF chromatin remodeling - SMARCB1, SMARCA4 (rhabdoid tumors, meningiomas)
- Succinate dehydrogenase complex - SDHA, SDHB, SDHC, SDHD, SDHAF2 (paraganglioma)
- Innate immune/antiviral - RNASEL, MSR1
- Transcription factors - WT1, MEN1, DICER1
Key Takeaway
~114-152 genes are well-validated germline cancer predisposition genes by current authoritative standards (Rahman 2014; TCGA 2018). Roughly 100 recognized familial cancer syndromes exist (Harrison's, 2025). With expanding genomic databases, the candidate list extends beyond 200 genes, though many still require clinical validation. The number will continue to grow as large-scale sequencing cohorts mature.
Key references:
- Rahman N. Nature 2014, PMID 24429628 - the foundational 114-gene catalog
- Huang et al. TCGA germline study, Cell 2018, PMID 29625052 - extended to 152 genes
- Harrison's Principles of Internal Medicine, 22nd ed. (2025), Table 76-3
- Sabiston Textbook of Surgery, Table 60.4
This is a shared conversation. Sign in to Orris to start your own chat.